🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Relevance of a Telemedicine Monitoring in the Management of Depression

RecruitingNAAges 18 Years - anyAllAssistance Publique - Hôpitaux de Paris
NCT06076317 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Major depressive disorder (MDD) is a common chronic disease. It is the main cause of morbidity and disability in the world with, among other things, an increase in cardio-metabolic risk and a reduction in life expectancy, regardless of suicide risk. MDD is the most expensive medical condition: 10-20 billion €/year in France. This cost is mainly attributable to the functional consequences of the disease, highlighting the medico-economic challenge represented by the optimization of the organization of care. In France, more than 80% of MDD patients are enrolled in non-psychiatric care pathways, mainly primary care or MSO hospital care (medicine, surgery, obstetrics). Unfortunately, less than half of patients benefit from treatment at an appropriate dosage or duration, thus exposing them to the risks of relapse, recurrence and chronic evolution. It is necessary to optimize this management,

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Presence of DSM5 criteria for the diagnosis of a characterized depressive episode * Patient hospitalized in MCO with request for liaison psychiatry opinion whatever the hospitalization modality (full hospitalization, weekday hospitalization or day hospitalization) * Initiation, change of molecule or modification of a psychotropic treatment (antidepressant or anxiolytic) during MCO hospitalization by the liaison psychiatrist * Affiliated or entitled to a social security system (except AME) * Obtaining free, written and informed consent Exclusion Criteria: * Severity of the depressive episode incompatible with outpatient care and relevant to an indication for hospitalization in psychiatry * Patient is part of a psychiatric care program at the time of the selection visit * Presence of a mood disorder other than CDD * Reason for MCO hospitalization secondary to psychiatric disorders, in particular suicide attempts * MCO hospitalization prolonged beyond 3 weeks after initiation, change of molecule or modification of psychotropic treatment dosage * Psychiatric comorbidities assessed by psychiatrist, in particular addictions (excluding tobacco), delusional disorders, post-traumatic stress disorder, anxiety disorders (excluding GAD) * High suicidal risk at the screening visit assessed by psychiatrist * Presence of a non-psychiatric condition with a vital prognosis of less than 3 years * Contraindications to telemedicine (no internet access, major vision problems, major cognitive problems, marked impulsivity, clinical situation requiring information to be communicated in person, etc.) * Conditions making consent impossible (major cognitive disorders, etc.) * Deprived of liberty or under a protective measure (guardianship or under curatorship) * Pregnant woman * Refusal of the patient
💊

What it tests

  • Telemedicine session
📍

Where

1 site
Hôpital Pitié Salpêtrière
Paris, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy